-
公开(公告)号：EP4406610A2
公开(公告)日：2024-07-31
申请号：EP24166976.1
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61P35/02
CPC分类号： C12N5/0636 , C12N2501/72720130101 , C07K16/2803 , A61K31/519 , A61K45/06 , A61K31/436 , A61K31/53 , C07K2317/62220130101 , C07K2319/0320130101 , C07K2317/7320130101 , A61P35/00 , A61P35/02 , A61P43/00 , A61K39/001112 , A61K2239/3820230501 , A61K39/4631 , A61K2239/2620230501 , A61K2239/4820230501 , A61K39/464412 , A61K2239/3120230501 , A61K39/4611 , A61K39/4636
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
公开(公告)号：EP3888674A1
公开(公告)日：2021-10-06
申请号：EP21160203.2
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61K39/00 , A61K35/17 , A61K31/436 , A61P35/02
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
3.发明公开TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR 审中-公开TOR UNG ON ON BS TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
公开(公告)号：EP3129470A1
公开(公告)日：2017-02-15
申请号：EP15719043.0
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl, H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David, L. , RUELLA, Marco , SELLERS, William, Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： C12N5/0783 , A61K35/17 , A61K31/00 , A61P35/02
CPC分类号： A61K35/17 , A61K31/436 , A61K31/519 , A61K31/53 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/03 , C12N5/0636 , C12N2501/599 , C12N2501/727 , C12N2510/00 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
摘要翻译： 本发明提供了用于治疗与CD19表达相关的疾病的组合物和方法，例如通过如本文所述施用包含本文所述的CD19 CAR的重组T细胞与激酶抑制剂，例如本文所述的激酶抑制剂组合。 本发明还提供了本文所述的试剂盒和组合物。
-
公开(公告)号：EP4406610A3
公开(公告)日：2024-10-30
申请号：EP24166976.1
申请日：2015-04-07
发明人： BYRD, John , DUBOVSKY, Jason , FRAIETTA, Joseph , GILL, Saar , GLASS, David , JOHNSON, Amy , JUNE, Carl H. , KENDERIAN, Saad , MANNICK, Joan , MAUS, Marcela , MURPHY, Leon , MUTHUSAMY, Natarajan , PORTER, David L. , RUELLA, Marco , SELLERS, William Raj , WASIK, Mariusz , BROGDON, Jennifer
IPC分类号： A61K39/00 , A61K35/17 , A61K31/436 , A61P35/02
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
-
5.发明公开COMBINATION OF CHIMERIC ANTIGEN RECEPTOR THERAPY AND AMINO PYRIMIDINE DERIVATIVES 审中-公开嵌合抗原受体疗法与氨基嘧啶衍生物的组合
公开(公告)号：EP3280795A1
公开(公告)日：2018-02-14
申请号：EP16718786.3
申请日：2016-04-07
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Byrd, John , Dubovsky, Jason , Johnson, Amy , June, Carl, H. , Muthusamy, Natarajan , Porter, David L. , Wasik, Mariusz
发明人： BYRD, John , DUBOVSKY, Jason , JOHNSON, Amy , JUNE, Carl, H. , MUTHUSAMY, Natarajan , PORTER, David, L. , WASIK, Mariusz , ANGST, Daniela , FRAIETTA, Joseph, A. , GESSIER, Francois , GILL, Saar , MAUS, Marcela , RUELLA, Marco , VULPETTI, Anna
IPC分类号： C12N5/0783 , A61K31/505 , A61K31/506 , A61K45/06
CPC分类号： A61K31/505 , A61K31/506 , A61K35/17 , A61K45/06 , A61K2035/124 , A61K2039/505 , A61K2039/545 , A61P35/00 , A61P35/02 , C07K16/2803 , C07K16/30 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2319/02 , C07K2319/03 , C12N5/0636 , A61K2300/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
-
-
-
-
搜索结果
5 条记录 (耗时 0.024 秒)
